Merck Sees Mixed Institutional Moves Following Strong Earnings and Pipeline News
Recent regulatory filings show shifting institutional stakes in Merck & Co., Inc. following third-quarter financial results that beat expectations and new pipeline developments across multiple clinical programs.
Institutional investors have recently adjusted their holdings in Merck & Co., Inc. (MRK), according to regulatory filings submitted to the Securities and Exchange Commission. M&G PLC reduced its stake by 86.6% during the third quarter, selling 182,653 shares to finish with 28,312 shares worth $4,105,000. Other firms moved in differing directions during the period. Beutel Goodman & Co Ltd. trimmed its position by 42.7% through the sale of 884,504 shares, and AEGON Asset Management UK Plc reduced its stake by 3.2%. Conversely, Vestor Capital LLC expanded its holdings by 16,530.7% by purchasing 27,441 shares, while Red Cedar Investment Management LLC raised its position by 33.2%. Institutional investors collectively hold 76.07% of the company's shares.
The position changes followed Merck's quarterly financial results delivered on Thursday, October 29th. The drugmaker reported earnings per share of $2.49, exceeding the consensus analyst estimate of $2.09. Revenue reached $18.09 billion, representing a 4.7% increase compared to the prior-year period and surpassing analyst projections of $17.33 billion. A dividend-stock comparison highlighted that Merck raised its 2026 sales outlook after the quarterly report.
Merck also announced several clinical pipeline updates. The company reported positive Phase 2b trial results for efinopegdutide, an investigational weekly treatment for patients with MASH and moderate-to-advanced liver fibrosis. Additionally, Merck initiated the Phase 3 ENHANCE-3 trial evaluating OHTUVAYRE for chronic obstructive pulmonary disease maintenance, and the Food and Drug Administration granted priority review to sacituzumab tirumotecan for endometrial cancer. Meanwhile, analyst commentary cautioned that generic competition, softer vaccine demand, and slowing growth for Keytruda could create revenue challenges in 2027.
On Wall Street, sentiment remains varied. MarketBeat reported that the stock carries an average consensus rating of "Moderate Buy" with an average price target of $155.74. Recent firm actions include Barclays setting an "overweight" rating with a $180.00 price target, JPMorgan Chase & Co. establishing an "overweight" rating at $175.00, and Freedom Broker assigning a "hold" rating with a $140.00 target. Zacks Research downgraded the shares to a "strong sell" rating on Monday, October 19th.
Separately, corporate insider disclosures revealed executive sales over the past three months totaling 102,014 shares valued at $13,608,779. Executive Vice President Chirfi Guindo sold 10,000 shares on Thursday, August 13th, at an average price of $135.00. Executive Vice President Richard Deluca sold 11,699 shares on Wednesday, August 12th, at an average price of $131.63. Corporate insiders hold 0.17% of Merck's common stock.